Determinants of the activities of antifolates delivered into cells by folate-receptor-mediated endocytosis
Authors:
- 7 April 2015
- journal article
- research article
- Published by Springer Nature in Cancer Chemotherapy and Pharmacology
- Vol. 75 (6) , 1163-1173
Abstract
Elements in the endocytic process that are determinants of the activities of antifolates delivered by folate-receptor alpha (FRα) were explored.Keywords
This publication has 39 references indexed in Scilit:
- BGC 945, a Novel Tumor-Selective Thymidylate Synthase Inhibitor Targeted to α-Folate Receptor–Overexpressing TumorsCancer Research, 2005
- Folate receptor expression in carcinomas and normal tissues determined by a quantitative radioligand binding assayAnalytical Biochemistry, 2005
- Antifolate Resistance in a HeLa Cell Line Associated With Impaired Transport Independent of the Reduced Folate CarrierClinical Cancer Research, 2004
- Selective Preservation of Pemetrexed Pharmacological Activity in HeLa Cells Lacking the Reduced Folate CarrierCancer Research, 2004
- Randomized Phase III Trial of Pemetrexed Versus Docetaxel in Patients With Non–Small-Cell Lung Cancer Previously Treated With ChemotherapyJournal of Clinical Oncology, 2004
- A review of folate receptor alpha cycling and 5-methyltetrahydrofolate accumulation with an emphasis on cell models in vitroAdvanced Drug Delivery Reviews, 2004
- The Role of α-Folate Receptor-Mediated Transport in the Antitumor Activity of Antifolate DrugsClinical Cancer Research, 2004
- Marked suppression of the activity of some, but not all, antifolate compounds by augmentation of folate cofactor pools within tumor cellsBiochemical Pharmacology, 2001
- Cellular pharmacology and in vivo activity of a new anticancer agent, ZD9331: a water-soluble, nonpolyglutamatable, quinazoline-based inhibitor of thymidylate synthase.1997
- Carrier- and receptor-mediated transport of folate antagonists targeting folate-dependent enzymes: correlates of molecular-structure and biological activity.Molecular Pharmacology, 1995